DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: OCREVUS (ocrelizumab)
       *****************************************************
       #Post#: 2891--------------------------------------------------
       1st PML case with ocrelizumab alone reported
   DIR By: agate
       Date: April 30, 2020, 6:57 pm
       ---------------------------------------------------------
       The first clear-cut case of PML in an MS patient taking Ocrevus
       has been reported--and the patient (age 78) died. Sad news
       indeed. From Medscape Neurology (April 30, 2020), "Report
       Details First Case of PML with Ocrelizumab Alone":
  HTML https://www.medscape.com/viewarticle/929728
       #Post#: 2892--------------------------------------------------
       Re: 1st PML case with ocrelizumab alone reported
   DIR By: agate
       Date: April 30, 2020, 7:08 pm
       ---------------------------------------------------------
       Here is the abstract of the report mentioned in the article
       cited in the previous post.
       AAN abstract (2020--exact date not given), "Progressive
       multifocal leukoencephalopathy in a patient on ocrelizumab
       monotherapy":
  HTML https://index.mirasmart.com/AAN2020/PDFfiles/AAN2020-004875.html
       The last sentence of the Conclusions section might be worth
       noting:
       --- Quote ---
       > This case emphasizes the importance of a thorough discussion
       of the risks and benefits of ocrelizumab, especially in patients
       at higher risk for infections, such as the elderly.
       --- End Quote ---
       #Post#: 2896--------------------------------------------------
       (Abst.) Risk factors in developing lymphopenia and
       hypogammaglobulinemia...
   DIR By: agate
       Date: May 6, 2020, 12:46 am
       ---------------------------------------------------------
       A paper prompted by this case (apparently) was presented to the
       AAN (American Academy of Neurology), which has scheduled virtual
       presentations of research papers in May and June instead of its
       usual annual meeting, which was canceled on account of COVID-19.
       This is the abstract of the paper, "Evaluation of risk factors
       in developing lymphopenia and hypogammaglobulinemia in anti-CD20
       treated multiple sclerosis patients":
  HTML https://index.mirasmart.com/AAN2020/PDFfiles/AAN2020-005218.html
       *****************************************************
       Page 1 of 1